Publication Name	World Journal of Experimental Medicine
Manuscript ID	17771
Country	Canada

Received	2015-03-23 15:29
Peer-Review Started	2015-03-25 19:45
To Make the First Decision	2015-04-10 17:40
Return for Revision	2015-04-17 10:48
Revised	2015-04-22 03:36
Second Decision	2015-06-12 16:34
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-06-19 17:57
Articles in Press	2015-06-19 17:57
Publication Fee Transferred
Edit the Manuscript by Language Editor	2015-06-25 00:51
Typeset the Manuscript	2015-08-13 20:20
Publish the Manuscript Online	2015-08-26 08:36

ISSN	2220-315x (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, Research & Experimental
Manuscript Type	Retrospective Study
Article Title	Eribulin for heavily pre-treated metastatic breast cancer patients
Manuscript Source	Invited Manuscript
All Author List	Antonia Digklia and Ioannis A Voutsadakis
Funding Agency and Grant Number
Corresponding Author	Ioannis A Voutsadakis, MD, PhD, Division of Medical Oncology, Department of Medicine, Sault Area Hospital, 750 Great Northern Road, Sault Ste Marie, Ontario ON P6B 0A8, Canada. ivoutsadakis@yahoo.com
Key Words	Breast cancer; Metastatic; Eribulin; Case series; Retrospective; Treatment
Core Tip	This report discusses treatment with eribulin in clinical practice outside a clinical trial setting. It confirms the activity of eribulin in a heavily pre-treated metastatic breast cancer population.
Publish Date	2015-08-26 08:36
Citation	Digklia A, Voutsadakis IA. Eribulin for heavily pre-treated metastatic breast cancer patients. World J Exp Med 2015; 5(3): 194-199
URL	http://www.wjgnet.com/2220-315X/full/v5/i3/194.htm
DOI	http://dx.doi.org/10.5493/wjem.v5.i3.194

Full Article (PDF)	WJEM-5-194.pdf
Full Article (Word)	WJEM-5-194.doc
Manuscript File	17771-Review.doc
Answering Reviewers	17771-Answering reviewers.pdf
Audio Core Tip	17771-Audio core tip.wma
Biostatistics Review Certificate	17771-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	17771-Conflict-of-interest statement.pdf
Copyright License Agreement	17771-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	17771-Institutional review board statement.pdf
Peer-review Report	17771-Peer-review(s).pdf
Scientific Misconduct Check	17771-Scientific misconduct check.pdf
Scientific Editor Work List	17771-Scientific editor work list.pdf